>this is all a big boondoggle motivated by my interest in understanding Merrimack's delay in reporting results. I am not assuming the worst like some.<
Nor am I given that:
1. GTC is projecting Q4 receipts from Merrimack for MM-093 clinical-trial supplies; and
2. GTC has increased (or is in the process of increasing) the size of the Merrimack goat herd.
Regards, Dew
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.